Navigation Links
Lilly Announces Retirement of Robert Armitage, Names Michael Harrington Senior Vice President and General Counsel

INDIANAPOLIS, Aug. 30, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Michael J. Harrington will be promoted to senior vice president and general counsel effective Jan. 1, 2013.  Harrington will replace Robert A. Armitage who will retire at the end of the year.

Harrington, vice president and deputy general counsel, is currently responsible for the legal function across Lilly's five business units.  In his new role, he will report to John Lechleiter, Ph.D., chairman, president, and CEO, and will serve on the company's executive committee.

Commenting on Armitage's career, Lechleiter stated, "Bob Armitage has left a lasting impact on Lilly and the biopharmaceutical industry with his exceptional contributions, particularly in the field of intellectual property. He also has provided keen insight and extraordinary leadership across a range of business issues affecting our company. It's been an absolute privilege to work with him."

Armitage played a major role in the successful efforts leading to the passage last year of the America Invents Act, which made the most sweeping changes to U.S. patent law in 175 years. In 2011, he became one of a select group of only 47 individuals who have been inducted in the Intellectual Property Hall of Fame, which includes U.S. presidents Jefferson and Madison. Armitage joined Lilly in 1999 as vice president and general patent counsel, Lilly Research Laboratories.  For the last decade, he has led Lilly's global legal organization as the company's general counsel.

Harrington is a graduate of the Columbia University School of Law. He joined the company in 1991 and has served in a number of business and legal positions with Lilly, including managing director of Eli Lilly New Zealand, general counsel for Lilly's Asia-Pacific operations and deputy general counsel with responsibility for all litigation, manufacturing, environmental and human resources matters.

"We are very fortunate to have Mike Harrington to take Bob's place. Mike is well-prepared for his new assignment. He has been instrumental in handling many of the key legal challenges we have faced in the last few years. His extensive global experience, deep knowledge of the business, and his passion for Lilly's mission will serve our company well," said Lechleiter.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information ─ for some of the world's most urgent medical needs. Additional information about Lilly is available at  C-LLY





SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
2. U.S. Court of Appeals Upholds Validity of Lillys Alimta Compound Patent
3. Lilly Revises 2012 Reported Guidance to Reflect Income from Early Payment of Amylin Obligations
4. Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures
5. Lilly Supports Research to Determine What a Dogs Nose Knows About People with Diabetes and Severe Hypoglycemia
6. Lilly Reports Second-Quarter 2012 Results, Raises 2012 EPS Guidance
7. Lilly Confirms Date and Conference Call for Second-Quarter 2012 Financial Results Announcement
8. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
9. Lilly Diabetes Announces Once Upon A Time Contest Winner
10. Lilly Statement on Affordable Care Act Ruling by Supreme Court
11. Lilly Statement on PDUFA Vote by Senate
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):